The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists (VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important because deviations from their narrow therapeutic window can result in bleedings due to over-anticoagulation or thrombosis because of under-anticoagulation. In addition to pharmacodynamic interactions (e.g., augmented bleeding risk for concomitant use of NSAIDs), interactions with drugs, foods, herbs, and over-the-counter medications may affect the risk/benefit ratio of VKAs. Direct oral anticoagulants (DOACs) including Factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and thrombin inhibitor (dabigatran) are poised to replace warfarin. Phase-3 studies and real-world evaluations have established that the safety profile of DOACs is superior to those of VKAs. However, some pharmacokinetic and pharmacodynamic interactions are expected. Herein we present a critical review of VKAs and DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications.

Old and new oral anticoagulants : food, herbal medicines and drug interactions / A. Di Minno, B. Frigerio, G. Spadarella, A. Ravani, D. Sansaro, M. Amato, J.P. Kitzmiller, M. Pepi, E. Tremoli, D. Baldassarre. - In: BLOOD REVIEWS. - ISSN 0268-960X. - (2017 Feb 05). [Epub ahead of print] [10.1016/j.blre.2017.02.001]

Old and new oral anticoagulants : food, herbal medicines and drug interactions

A. Di Minno
Primo
;
B. Frigerio
Secondo
;
G. Spadarella;E. Tremoli
Penultimo
;
D. Baldassarre
Ultimo
2017

Abstract

The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists (VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important because deviations from their narrow therapeutic window can result in bleedings due to over-anticoagulation or thrombosis because of under-anticoagulation. In addition to pharmacodynamic interactions (e.g., augmented bleeding risk for concomitant use of NSAIDs), interactions with drugs, foods, herbs, and over-the-counter medications may affect the risk/benefit ratio of VKAs. Direct oral anticoagulants (DOACs) including Factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and thrombin inhibitor (dabigatran) are poised to replace warfarin. Phase-3 studies and real-world evaluations have established that the safety profile of DOACs is superior to those of VKAs. However, some pharmacokinetic and pharmacodynamic interactions are expected. Herein we present a critical review of VKAs and DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications.
Co-morbidities; Direct anticoagulant drugs; Loss of efficacy; Patients characteristics; Therapeutic context; Thrombotic/bleeding events; Toxicity; Warfarin
Settore BIO/14 - Farmacologia
5-feb-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0268960X16300352-main.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 708.26 kB
Formato Adobe PDF
708.26 kB Adobe PDF Visualizza/Apri
1-s2.0-S0268960X16300352-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.51 MB
Formato Adobe PDF
1.51 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/476466
Citazioni
  • ???jsp.display-item.citation.pmc??? 75
  • Scopus 184
  • ???jsp.display-item.citation.isi??? 172
social impact